The Mounjaro lawsuit landscape shifted dramatically on July 1, 2026, when MDL 3094 — formally known as In re: GLP-1 RAs Products Liability Litigation — crossed a striking milestone: 3,848 pending cases before Judge Karen S. Marston in the Eastern District of Pennsylvania. That figure represents a near-doubling from the 1,809 cases recorded in May 2025 and a jump from 3,063 in January 2026, signaling that this litigation is accelerating, not plateauing. With Eli Lilly’s Daubert motion pending, a Medicare deal expected to expose millions more patients to the same drug molecule, and no bellwether trial date on the calendar, the next ruling from Judge Marston could either reshape or effectively end thousands of claims. Here is what injured patients and their families need to understand right now.
MDL 3094 Case-Count Milestone: What 3,848 Cases Means for Plaintiffs
MDL 3094 consolidates product liability claims against Eli Lilly, the sole defendant for tirzepatide-based injuries. Both Mounjaro — FDA-approved for type 2 diabetes in 2022 — and Zepbound — FDA-approved for weight management in 2023 — contain the same active molecule, tirzepatide. Plaintiffs across both drug brands allege that Eli Lilly failed to adequately warn prescribers and patients about the risk of severe gastrointestinal injuries, including gastroparesis (stomach paralysis), ileus, and bowel obstruction.
The pace of new filings reflects the scale of public exposure. Mounjaro and Zepbound together generated $24.8 billion in revenue in just the first nine months of 2025, accounting for 54% of Eli Lilly’s total company revenue. That commercial dominance — built on tens of millions of prescriptions — is now the backdrop against which thousands of injured plaintiffs are seeking accountability. The federal court caseload statistics from uscourts.gov underscore how unusual it is for an MDL to nearly double in under 14 months, placing this litigation among the most rapidly growing pharmaceutical mass torts in recent memory.
Important to note: compounded versions of tirzepatide purchased through telehealth platforms or compounding pharmacies are not eligible for inclusion in MDL 3094. Only patients who used FDA-approved Mounjaro or Zepbound manufactured by Eli Lilly may qualify as plaintiffs in this litigation.
Eli Lilly’s Daubert Motion: The Most Consequential Pending Decision
No ruling in the Mounjaro lawsuit carries higher stakes than Eli Lilly’s pending Daubert motion. The company has asked Judge Marston to exclude plaintiffs’ expert witnesses and, by extension, to dismiss entire categories of claims. Under Daubert v. Merrell Dow Pharmaceuticals, federal judges serve as gatekeepers for scientific testimony — if Judge Marston rules that plaintiffs’ experts cannot reliably establish medical causation, thousands of cases could be dismissed before a single trial takes place.
Daubert hearings in the broader GLP-1 MDL began in May 2025. Case Management Order No. 30, entered in January 2026, drove subsequent expert disclosures and Daubert briefing. Expert depositions concluded by the March 27, 2026 deadline, and summary judgment motions were filed by April 16, 2026. As of July 2026, no formal bellwether trial date has been set — meaning the outcome of the Daubert hearing will dictate the litigation’s entire trajectory. Eli Lilly also raises a preemption defense, arguing that because Mounjaro’s labeling was approved by the FDA, state-law failure-to-warn claims are federally preempted. Plaintiffs counter that the December 2025 FDA label update — which strengthened warnings about severe GI reactions and acute pancreatitis — proves the original labeling was inadequate. You can review the legal standards governing expert admissibility at Cornell Law School’s Legal Information Institute, Federal Rule of Evidence 702.
If you believe you were harmed by a defective pharmaceutical product and want to understand what your claim may be worth, using a medical malpractice calculator can give you a preliminary sense of how courts value injuries from drug company negligence — though individual outcomes depend heavily on case-specific facts and applicable law.
Key Mounjaro Lawsuit Statistics at a Glance
| Data Point | Figure | Date / Source Context |
|---|---|---|
| Pending MDL 3094 cases | 3,848 | July 1, 2026 (Motley Rice / Drugwatch) |
| Cases in January 2026 | 3,063 | January 2026 court records |
| Cases in May 2025 | 1,809 | May 2025 court records |
| FDA adverse events (Mounjaro, since 2022) | 35,220 total; 3,271 serious; 133 deaths | FDA FAERS database |
| Mounjaro/Zepbound combined revenue (9 mos. 2025) | $24.8 billion (54% of Lilly revenue) | Eli Lilly financial reports |
| NAION vision-loss MDL 3163 cases | 146 | June 2026 |
| Estimated settlement — severe gastroparesis | $400,000 – $700,000 | Legal analyst projections |
| Estimated settlement — vision-loss cases | Potentially exceeding $1,000,000 | Legal analyst projections |
| New Medicare patients expected to access Zepbound | ~10 million | Trump administration 2026 Medicare deal |
The Medicare Deal, FDA Label Changes, and a Growing Plaintiff Pool
In 2026, the Trump administration finalized a Medicare deal expected to provide approximately 10 million additional patients access to Zepbound at roughly $50 per month — compared to several hundred dollars per month at private market prices. Because Zepbound and Mounjaro share the identical tirzepatide molecule, this policy decision directly expands the population of individuals who may develop the same gastrointestinal injuries already at the center of the Mounjaro lawsuit. Litigation attorneys are watching carefully, as new prescriptions today could translate into new case filings over the coming one to three years as injuries manifest and are diagnosed.
The December 2025 FDA label update is equally significant. The agency strengthened Mounjaro’s warnings regarding severe GI reactions and acute pancreatitis — a move plaintiffs will use as direct evidence that Eli Lilly’s pre-update labeling was insufficient. A separate June 2025 FDA label update had already added warnings about acute kidney injury. The FDA’s drug safety database records both label amendments, and plaintiffs’ attorneys are expected to introduce these regulatory actions prominently during any future bellwether trials. The FDA’s Adverse Events Reporting System (FAERS) has logged 35,220 adverse events attributed to Mounjaro since 2022, including 3,271 serious cases and 133 deaths — a dataset that will feature heavily in expert testimony.
How to Qualify Under Judge Marston’s Gastric Emptying Study Requirement
One of the most practically important rulings already issued in MDL 3094 is Judge Marston’s August 2025 order requiring plaintiffs alleging gastroparesis to document their diagnosis with gastric emptying scintigraphy (GES). This nuclear medicine test measures how quickly food moves through the stomach and is the clinical gold standard for diagnosing gastroparesis. Without GES documentation, gastroparesis claims will not survive in the MDL under current court orders.
If you took Mounjaro or Zepbound and experienced chronic nausea, vomiting, feeling full after small amounts of food, bloating, or abdominal pain — symptoms that persisted long after you stopped the medication — you should ask your physician about undergoing a gastric emptying study. Documented, objective test results establish the medical foundation that Judge Marston requires. Patients who were hospitalized for bowel obstruction or ileus should gather all hospital records, imaging results, and surgical notes. For those exploring what a serious gastrointestinal injury claim might be worth before contacting an attorney, a personal injury settlement calculator can provide a general framework based on injury severity and documented medical costs.
Severe gastroparesis cases — defined by prolonged hospitalization, feeding tube placement, or inability to maintain oral nutrition — are estimated by legal analysts to fall in the $400,000 to $700,000 settlement range. Cases involving permanent or near-permanent disability will command values at the higher end of that range.
Vision-Loss, Antitrust, and the Expanding Legal Frontier
The Mounjaro lawsuit universe extends beyond MDL 3094. A separate MDL — MDL 3163 — consolidates claims involving non-arteritic anterior ischemic optic neuropathy (NAION), a form of vision loss. As of June 2026, MDL 3163 contains 146 pending cases. Plaintiffs cite a study published in JAMA Ophthalmology in July 2024 and related research in JAMA Network Open finding that GLP-1 drug users are nearly twice as likely to develop NAION compared to patients on other diabetes medications. Legal analysts project that vision-loss cases — particularly those resulting in permanent visual impairment — could exceed $1 million per plaintiff given the life-altering nature of the injury. Fatal cases tied to GLP-1 medications may warrant consultation about a wrongful death calculator to understand the full economic and non-economic value of a claim.
On the antitrust front, Strive Specialties filed suit in January 2026 alleging that Eli Lilly and Novo Nordisk conspired to block telehealth platforms from collaborating with compounding pharmacies — effectively eliminating lower-cost access to GLP-1 drugs for patients. A separate class action targets CVS Caremark for dropping Zepbound from its formulary in late 2025, harming patients who depended on insurance coverage. The Texas Attorney General has also filed suit accusing Eli Lilly of illegal sales practices. These parallel proceedings — combined with the expectation that internal company communications unearthed in discovery will become a focal point — paint a picture of litigation pressure on Eli Lilly expanding across multiple legal fronts simultaneously. More information on how antitrust statutes interact with pharmaceutical pricing can be found through the U.S. Department of Justice Antitrust Division.
No global settlement in MDL 3094 has been announced as of July 2026. Until the Daubert ruling is issued and at least one bellwether trial is completed — establishing what juries believe about causation and damages — Eli Lilly has little structural incentive to negotiate global resolution. Plaintiffs and their legal teams should prepare for a litigation timeline extending into 2027 and potentially beyond.
Frequently Asked Questions About the Mounjaro Lawsuit
What injuries qualify for inclusion in the Mounjaro lawsuit MDL?
The primary injuries covered in MDL 3094 are gastroparesis (stomach paralysis), ileus, and bowel obstruction alleged to have been caused or worsened by tirzepatide in Mounjaro or Zepbound. Judge Marston’s August 2025 court order requires that gastroparesis plaintiffs provide gastric emptying scintigraphy (GES) test documentation to support their claims. Separate litigation — MDL 3163 — covers NAION vision-loss injuries linked to GLP-1 medications. Compounded tirzepatide from non-Eli Lilly sources does not qualify.
What is the current status of the Daubert motion in MDL 3094?
As of July 2026, Eli Lilly’s Daubert motion to exclude plaintiffs’ expert witnesses remains pending before Judge Karen S. Marston. Daubert hearings in the broader GLP-1 MDL began in May 2025. Expert depositions concluded March 27, 2026, and summary judgment motions were filed by April 16, 2026. The Daubert ruling is the single most consequential pending decision because an adverse ruling for plaintiffs could result in dismissal of entire categories of cases before any trial occurs.
How much could a Mounjaro lawsuit settlement be worth?
Legal analysts project that severe gastroparesis claims — involving prolonged hospitalization, surgical intervention, or permanent digestive impairment — may settle in the range of $400,000 to $700,000. Vision-loss cases in MDL 3163 involving permanent NAION damage are projected to potentially exceed $1 million. These figures are estimates based on comparable pharmaceutical mass tort settlements and are not guarantees. Actual values depend on injury severity, documented medical costs, lost income, and the specific facts of each plaintiff’s case. No global settlement has been announced as of July 2026.
How does the 2026 Medicare deal affect the Mounjaro lawsuit?
The Trump administration’s 2026 Medicare deal is expected to provide approximately 10 million additional patients access to Zepbound — which contains the same tirzepatide molecule as Mounjaro — at approximately $50 per month. This policy substantially expands the population of users who may develop gastrointestinal or other injuries linked to tirzepatide over the coming years. Attorneys anticipate that the Medicare expansion will generate new case filings well into 2027 and beyond as newly exposed patients develop diagnosed injuries and seek legal recourse.
Does the December 2025 FDA label update help plaintiffs in the Mounjaro lawsuit?
Yes. The December 2025 FDA decision to strengthen Mounjaro’s warning label regarding severe GI reactions and acute pancreatitis is expected to be powerful evidence for plaintiffs. Under a failure-to-warn legal theory, plaintiffs argue that Eli Lilly knew or should have known about these risks earlier and failed to adequately disclose them to prescribing physicians and patients. The fact that the FDA required a stronger label supports the argument that prior warnings were legally insufficient. A separate June 2025 FDA update adding acute kidney injury warnings is additional evidence plaintiffs intend to use in discovery and at trial.
Legal Disclaimer: The information provided on this page is for general informational purposes only and does not constitute legal advice, nor does it create an attorney-client relationship of any kind.
Related reading: Ozempic & GLP-1 Agonist Gastrointestinal Injury: Damages Calculator & Lawsuit Settlement Values 2026
Related reading: Medical Malpractice Statute Of Limitations (2026): Every State’s Deadline, Discovery Rule & Tolling Exception Explained
Victoria Chambers is a mass tort and class action research analyst with extensive knowledge of multi-district litigation (MDL), defective product cases, dangerous drug lawsuits, and toxic exposure claims across the United States. Victoria is not an attorney and the information provided is for educational purposes only.